Gene · 54890
Papers4,144
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
661 to 680 of 4,144
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Effects of RNA methylation on Tumor angiogenesis and cancer progression. | Mol Cancer | 2023 | 38053093 | PubTator, text mining | PubMed |
| Key m6A regulators mediated methylation modification pattern and immune infiltration characterization in hepatic ischemia-reperfusion injury. | BMC Med Genomics | 2023 | 38049811 | PubTator, text mining | PubMed |
| METTL16 in human diseases: What should we do next? | Open Med (Wars) | 2023 | 38045858 | PubTator, text mining | PubMed |
| RNA N6-methyladenosine-modified-binding protein YTHDF1 promotes prostate cancer progression by regulating androgen function-related gene TRIM68. | Eur J Med Res | 2023 | 38042806 | PubTator, text mining | PubMed |
| The role of post-transcriptional regulation in SARS-CoV-2 infection and pathogenicity. | Front Immunol | 2023 | 38035086 | PubTator, text mining | PubMed |
| Expression and Prognostic Value of m6A RNA Methylation-Related Genes in Thyroid Cancer. | Iran J Public Health | 2023 | 38033847 | PubTator, text mining | PubMed |
| Identification and validation of N6-methyladenosine (m6A)-related lncRNAs signature for predicting the prognosis of laryngeal carcinoma, especially for smoking patients. | Front Genet | 2023 | 38028627 | PubTator, text mining | PubMed |
| M6A RNA methylation modification and tumor immune microenvironment in lung adenocarcinoma. | Biophys Rep | 2023 | 38028153 | PubTator, text mining | PubMed |
| Global m6A methylation and gene expression patterns in human microglial HMC3 cells infected with HIV-1. | Heliyon | 2023 | 38027859 | PubTator, text mining | PubMed |
| Diagnostic Values of METTL1-Related Genes and Immune Characteristics in Systemic Lupus Erythematosus. | J Inflamm Res | 2023 | 38026241 | PubTator, text mining | PubMed |
| Do RNA modifications contribute to modulation of immune responses in allergic diseases? | Front Allergy | 2023 | 38026133 | PubTator, text mining | PubMed |
| N6-methyladenosine of TRIM27 enhances the stem cell-type phenotype of cisplatin-resistant colorectal cancer cells. | Biochem Biophys Rep | 2023 | 38024865 | PubTator, text mining | PubMed |
| m6A epitranscriptome analysis reveals differentially methylated transcripts that drive early chemoresistance in bladder cancer. | NAR Cancer | 2023 | 38023731 | PubTator, text mining | PubMed |
| m6A regulates breast cancer proliferation and migration through stage-dependent changes in Epithelial to Mesenchymal Transition gene expression. | Front Oncol | 2023 | 38023205 | PubTator, text mining | PubMed |
| Modulatory Effect of Vitamin C on Hypoxia Induced Breast Cancer Stem Cells. | Adv Pharm Bull | 2023 | 38022819 | PubTator, text mining | PubMed |
| Integrated analysis of single-cell RNA-seq and bulk RNA-seq reveals RNA N6-methyladenosine modification associated with prognosis and drug resistance in acute myeloid leukemia. | Front Immunol | 2023 | 38022588 | PubTator, text mining | PubMed |
| m6A demethylase FTO and osteoporosis: potential therapeutic interventions. | Front Cell Dev Biol | 2023 | 38020896 | PubTator, text mining | PubMed |
| circSLCO1B7 suppresses the malignant progression of hepatocellular carcinoma via the miR-556-3p/DAB2IP axis. | Aging (Albany NY) | 2023 | 38015711 | PubTator, text mining | PubMed |
| Research progress of N6-methyladenosine in colorectal cancer: A review. | Medicine (Baltimore) | 2023 | 38013272 | PubTator, text mining | PubMed |
| Therapeutic effect and transcriptome-methylome characteristics of METTL3 inhibition in liver hepatocellular carcinoma. | Cancer Cell Int | 2023 | 38012755 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/54890/papers?page=34